Kenneth Shain

Multiple Myeloma: New Insights and Therapeutic Approaches.

Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines.

Regulation of caspase expression and apoptosis by adenomatous polyposis coli.

Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.

Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells.

Targeting the bone marrow microenvironment in hematologic malignancies.

Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects.

Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIP.

Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation.

Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.

Environmental-mediated drug resistance: a target for multiple myeloma therapy.

Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience.

Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.

Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma.

Metastatic myeloma?

Stemness of B-cell progenitors in multiple myeloma bone marrow.

Sequence of novel agents in multiple myeloma: an instrumental variable analysis.

Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma.

A preclinical assay for chemosensitivity in multiple myeloma.

An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma.

Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides.

A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.